Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia
- 2 December 2009
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 36 (4) , 612-620
Abstract
To assess the effect on survival of macrolides or fluoroquinolones in intubated patients admitted to the intensive care unit (ICU) with severe community-acquired pneumonia (severe CAP).Keywords
This publication has 39 references indexed in Scilit:
- Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care unitsCritical Care Medicine, 2009
- Adjunctive Therapy in Community-Acquired PneumoniaSeminars in Respiratory and Critical Care Medicine, 2009
- Impact of intravenous -lactam/macrolide versus -lactam monotherapy on mortality in hospitalized patients with community-acquired pneumoniaJournal of Antimicrobial Chemotherapy, 2009
- Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter?Critical Care, 2009
- Placebo‐Controlled Trials of Treatments for Community‐Acquired Pneumonia: Review of the Literature and Discussion of Feasibility and Potential ValueClinical Infectious Diseases, 2008
- Adherence to guidelines’ empirical antibiotic recommendations and community-acquired pneumonia outcomeEuropean Respiratory Journal, 2008
- Respiratory tract infections: at-risk patients, who are they?: Implications for their management with levofloxacinInternational Journal of Antimicrobial Agents, 2006
- Antibacterial Dosing in Intensive CareClinical Pharmacokinetics, 2006
- Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent aloneEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000